|
|
Article: GLAXO INC. RECEIVES CLEARANCE TO MARKET IMITREX INJECTION
- Article from:
- PR Newswire
- Article date:
- December 29, 1992
CopyrightCOPYRIGHT 1992 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
RESEARCH TRIANGLE PARK, N.C., Dec. 29 /PRNewswire/ -- Cerenex Pharmaceuticals, a division of Glaxo Inc., announced today that it has received clearance from the U.S. Food and Drug Administration to market Imitrex (sumatriptan succinate) Injection, a new medication given by subcutaneous injection (beneath the skin) for the acute treatment of migraine.
Imitrex will be available to consumers by prescription in late March 1993.
"Migraine takes a tremendous toll on the sufferer's quality of life," said Roger Cady, M.D., medical director, Shealy Institute for Comprehensive Care in Springfield, Mo. "Many people are so debilitated by their symptoms that they are unable to ...